- Short communication
- Open Access
MicroRNA-21 inhibits p57Kip2 expression in prostate cancer
© Mishra et al.; licensee BioMed Central Ltd. 2014
Received: 5 June 2014
Accepted: 9 September 2014
Published: 12 September 2014
p57Kip2, a cyclin-dependent kinase inhibitor, is considered to be a candidate tumor suppressor gene that has been implicated in Beckwith-Wiedemann syndrome and sporadic cancers. In addition, decreased expression of p57Kip2 protein has been frequently observed in pancreatic, lung, breast, bladder, gastrointestinal tract and prostate cancers. However, p57Kip2 gene mutations are rare in these cancers suggesting that other unknown mechanisms might be at play in reducing its expression. The aim of this study was to investigate the molecular mechanism of down-regulation of p57Kip2 in prostate cancer.
We observed a significant negative correlation between the expression of p57Kip2 and microRNA-21 (miR-21) in prostate cancer samples and after androgen deprivation with castration in the CWR22 human prostate cancer xenograft model. We report that miR-21 targeted the coding region and decreased p57Kip2 mRNA and protein levels in prostate cancer cells. Conversely, inhibition of endogenous miR-21 by an anti-miR-21 inhibitor strongly induced p57Kip2 expression. Furthermore, we found that knockdown of p57Kip2 reversed the effects of the anti-miR-21 inhibitor on cell migration and anchorage-independent cell growth.
Our results indicate that miR-21 is able to downregulate p57Kip2 expression by targeting the coding region of the gene and is also able to attenuate p57Kip2 mediated functional responses. This is the first report demonstrating that p57Kip2 is a novel target of miR-21 in prostate cancer and revealing a novel oncogenic function of this microRNA.
Uncontrolled cell proliferation due to aberrant regulation of cell cycle control can lead to the development of cancer. Cyclin dependent kinase inhibitors (CKIs) are the common inhibitors of cell cycle which consists of two families: INK4 family (consisting of p16INK4a, p15INK4b, p18INK4c and p19INK4d) and Cip/Kip family (p21CIP1/WAF1, p27Kip2 and p57Kip2) . Human p57Kip2 gene is maternally expressed and paternally imprinted and is located on chromosome 11p15.5 , which is implicated in Beckwith-Wiedemann syndrome  and in sporadic cancers. p57Kip2 is also required for normal development as p57Kip2 null mice die at 2 weeks of age and show increased apoptosis and delayed differentiation during mouse development . Because of its chromosomal location, imprinting status and functional activities, p57Kip2 is considered to be a candidate tumor suppressor gene. p57Kip2 overexpression in LNCaP prostate cancer cells resulted in the conversion of adenocarcinoma to a more differentiated squamous tumor in nude mice, with reduced cell proliferation and tumor invasion . p57Kip2 is considered to be a tumor suppressor gene since it functions to block cell proliferation by inhibiting cell cycle progression, promotes apoptosis and cell differentiation, inhibits tissue invasion and metastasis and also inhibits angiogenesis . Hence, cancer cells frequently down-regulate p57Kip2 in order to gain a proliferative advantage.
Loss of or reduced p57Kip2 expression occurs in carcinomas of the prostate, bladder, liver, pancreas, breast and others. The absence of p57Kip2 gene mutations in a wide variety of cancers suggests that other transcriptional or post-transcriptional mechanisms might be involved in its down-regulated protein expression. Inactivation of p57Kip2 gene due to promoter DNA methylation was observed in non-small cell lung cancer and in lymphoid malignancies of B-cells [7, 8]. Yang et al. found that p57Kip2 expression in breast cancer cells was repressed due to Polycomb protein EZH2-mediated H3K27me3 chromatin mark. Increased p57Kip2 degradation due to ubiquitylation by E3 ligase Skp1/ Cul1/ F-box (SCF complex) was observed in non-small cell lung carcinoma and hepatocellular carcinoma [9, 10].
Mature miRNAs are ~22 nucleotides long non-coding single-stranded RNAs, which upon binding to the 3’-UTR region of target mRNAs can result in mRNA cleavage, or translational repression. p57Kip2 has been reported to be targeted by miR-221/222 cluster in gastric carcinoma, ovarian cancer and hepatocellular carcinoma . miR-92b and miR-25 have also been reported to down-regulate p57Kip2 expression in human embryonic stem cells and in gastric cancer respectively [12, 13]. Jin et al. demonstrated that expression of p57Kip2 is significantly decreased in human prostate cancer and overexpression of p57Kip2 in prostate cancer cells decreased cell proliferation and reduced invasiveness . However, the mechanism behind p57Kip2 down-regulation in prostate cancer cells has not been investigated. Unexpectedly, we discovered that p57Kip2 is one of the novel downstream target genes of miR-21 in prostate cancer. We observed a very strong negative correlation between p57Kip2 and miR-21 expression in human prostate tumor samples and in CWR22, a human prostate cancer xenograft model. Our results for the first time show that miR-21 can down-regulate p57Kip2 mRNA and protein expression by targeting its coding region to attenuate its activity in prostate cancer cells. Thus, therapeutic approaches aimed at restoring p57Kip2 expression might be beneficial for prostate cancer prevention and therapy.
Findings and discussion
MicroRNA-21 targets p57Kip2 gene
MicroRNA-21 downregulates p57Kip2 expression
MicroRNA-21 abrogates p57Kip2-mediated functional responses in prostate cancer cells
In summary, we discovered p57Kip2 to be a novel target gene of microRNA-21 in prostate cancer. Our findings provide a novel mechanism of p57Kip2 downregulation in prostate cancer. These findings warrant further research to test if p57Kip2 is also a novel target gene of miR-21 in other cancer types as well. In our previous study, we found miR-21 to be an oncogenic regulator in prostate cancer by targeting the tumor suppressive effects of TGF-beta signaling pathway in cancer cells . Given, the regulation of p57Kip2 by microRNA-21 in the current study, we provide a strong rationale to perform preclinical testing of microRNA-21 inhibitor as a novel therapeutic drug for prostate cancer.
We thank Dr. Majeet Rao for the pMIR luciferase construct and Dr. Clifford G. Tepper for the CWR22 xenograft tissue. This work was supported in part by funding from NIH grants RO1CA079683, RO1CA172886, and P30CA054174.
- Park MT, Lee SJ: Cell cycle and cancer. J Biochem Mol Biol. 2003, 36: 60-65. 10.5483/BMBRep.2003.36.1.060View ArticlePubMedGoogle Scholar
- Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ: p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995, 9: 650-662. 10.1101/gad.9.6.650View ArticlePubMedGoogle Scholar
- Lam WW, Hatada I, Ohishi S, Mukai T, Joyce JA, Cole TR, Donnai D, Reik W, Schofield PN, Maher ER: Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J Med Genet. 1999, 36: 518-523.PubMed CentralPubMedGoogle Scholar
- Yan Y, Frisen J, Lee MH, Massague J, Barbacid M: Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 1997, 11: 973-983. 10.1101/gad.11.8.973View ArticlePubMedGoogle Scholar
- Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW, Wills ML, Logan SK, Zhang P, Matusik RJ: Down-regulation of p57Kip2 induces prostate cancer in the mouse. Cancer Res. 2008, 68: 3601-3608. 10.1158/0008-5472.CAN-08-0073View ArticlePubMedGoogle Scholar
- Kavanagh E, Joseph B: The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta. 1816, 2011: 50-56.Google Scholar
- Li Y, Nagai H, Ohno T, Yuge M, Hatano S, Ito E, Mori N, Saito H, Kinoshita T: Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood. 2002, 100: 2572-2577. 10.1182/blood-2001-11-0026View ArticlePubMedGoogle Scholar
- Hagiwara K, Li Y, Kinoshita T, Kunishma S, Ohashi H, Hotta T, Nagai H: Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma. Leuk Res. 2010, 34: 50-54. 10.1016/j.leukres.2009.06.028View ArticlePubMedGoogle Scholar
- Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, Hatakeyama S, Nakayama K, Nakayama KI: Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A. 2003, 100: 10231-10236. 10.1073/pnas.1831009100PubMed CentralView ArticlePubMedGoogle Scholar
- Calvisi DF, Pinna F, Ladu S, Muroni MR, Frau M, Demartis I, Tomasi ML, Sini M, Simile MM, Seddaiu MA, Feo F, Pascale RM: The degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase is genetically controlled in rodent liver cancer and contributes to determine the susceptibility to the disease. Int J Cancer J Int du Cancer. 2010, 126: 1275-1281.Google Scholar
- Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, Negrini M: MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008, 27: 5651-5661. 10.1038/onc.2008.178View ArticlePubMedGoogle Scholar
- Sengupta S, Nie J, Wagner RJ, Yang C, Stewart R, Thomson JA: MicroRNA 92b controls the G1/S checkpoint gene p57 in human embryonic stem cells. Stem Cells. 2009, 27: 1524-1528. 10.1002/stem.84View ArticlePubMedGoogle Scholar
- Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK, Kim VN: Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 2009, 37: 1672-1681. 10.1093/nar/gkp002PubMed CentralView ArticlePubMedGoogle Scholar
- Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM, Stein GS: MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 2008, 68: 2773-2780. 10.1158/0008-5472.CAN-07-6754PubMed CentralView ArticlePubMedGoogle Scholar
- Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H: Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 2005, 65: 4218-4227. 10.1158/0008-5472.CAN-04-4407View ArticlePubMedGoogle Scholar
- Mishra S, Deng JJ, Gowda PS, Rao MK, Lin CL, Chen CL, Huang T, Sun LZ: Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene. 2014, 33: 4097-4106. 10.1038/onc.2013.374PubMed CentralView ArticlePubMedGoogle Scholar
- Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, Santella RM: Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012, 72: 1469-1477. 10.1002/pros.22499PubMed CentralView ArticlePubMedGoogle Scholar
- Hausser J, Syed AP, Bilen B, Zavolan M: Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation. Genome Res. 2013, 23: 604-615. 10.1101/gr.139758.112PubMed CentralView ArticlePubMedGoogle Scholar
- Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG: CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res. 1996, 56: 3042-3046.PubMedGoogle Scholar
- Guo H, Lv Y, Tian T, Hu TH, Wang WJ, Sui X, Jiang L, Ruan ZP, Nan KJ: Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma. Carcinogenesis. 2011, 32: 1897-1904. 10.1093/carcin/bgr220View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.